Tecnis multifocal approved by FDA

Article

The Tecnis multifocal intraocular lens (IOL) has been approved by the FDA, according to an announcement made by AMO, the manufacturer of the lens.

The Tecnis multifocal intraocular lens (IOL) has been approved by the FDA, according to an announcement made by AMO, the manufacturer of the lens.

Tecnis is indicated to correct aphakia in adult patients with or without presbyopia following phacoemulsification. The lens provides high quality near, intermediate and distance vision in a range of light conditions (both day and night) for 94% of patients. It has a pupil-independent, non-apodized diffractive aspheric surface to reduce chromatic aberration, and almost nine out of every 10 patients implanted with the lens were found to be spectacle-independent after surgery.

The multifocal, which is already available in Europe, will be available to surgeons in the US sometime early this year.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.